Latest Administration News

Sunshine Metals Limited reported a solid cash position of AUD 5.1 million at the end of Q3 2025, supported by a strong financing inflow that offsets ongoing exploration expenditures.

Arovella Therapeutics has secured encouraging feedback from the US FDA on reagent testing for its CAR-iNKT cell therapy, setting the stage for an IND filing this quarter and clinical trials in early 2026.

Syntara Limited reports encouraging Phase 2a results for amsulostat in myelofibrosis, with significant symptom relief and spleen volume reduction sustained over 12 months, alongside new clinical trial initiations and a solid cash position.

Develop Global Limited reported a robust cash position of $203.8 million at the end of September 2025, supported by a significant $161 million inflow from financing activities. Despite operating and investing cash outflows, the company maintains a strong liquidity runway.

DevEx Resources has made significant progress in its uranium and rare earth exploration programs, completing key surveys and preparing for drilling in 2026. Early assay results and metallurgical tests highlight promising prospects across its Northern Territory and Queensland projects.

Kingfisher Mining secures shareholder approval for NSW tenement acquisition and accelerates exploration at Copper Blow and Mick Well REE projects, backed by a solid $2.35 million cash position.

Cosmos Exploration deepens its foothold in Bolivia’s lithium sector through advanced brine testing and a strategic pilot plant purchase, positioning itself at the forefront of sustainable lithium extraction.

E79 Gold Mines Limited reported a net cash outflow of AUD 827,000 for the September 2025 quarter but bolstered its financial position through a successful capital raising in October. The company plans to reduce exploration expenditure in the coming quarter while maintaining operational continuity.

Brazilian Critical Minerals Limited reported a net cash outflow of AUD 1.2 million for Q3 2025, offset by strong financing inflows that boosted its cash reserves to AUD 2.46 million. The company’s extended loan facility and available credit provide a runway of over five quarters at current spending levels.

Corella Resources reports a cautious quarter with a $424,000 cash balance as it reassesses exploration plans at its Tampu Project and considers new ventures to boost shareholder value.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

PYC Therapeutics has reported significant progress across its four RNA therapeutic programs targeting genetic diseases, alongside a strong cash runway supporting ongoing development.